Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
- A$10.84 million FY2026 R&D tax incentive rebate received
- A$5.99 million net cash proceeds after repaying Endpoints Capital
- A$21.9 million pro forma quarter-end cash position
- No debt following repayment of the A$4.3 million advance
- XanaMIA topline results expected in mid-November
R&D Rebate Lifts Actinogen’s Cash Position
Actinogen Medical (ASX:ACW) has secured a timely cash injection ahead of its most important clinical milestone, receiving an A$10.84 million research and development tax incentive rebate from the Australian Taxation Office for FY2026, including interest.
The headline figure overstates the immediate funding benefit because Actinogen had already borrowed A$4.3 million from Endpoints Capital against the expected rebate. That advance, plus interest, has now been repaid, leaving the company with net proceeds of A$5.99 million and no debt.
Debt-Free Balance Sheet Before XanaMIA Readout
Combined with approximately A$15.9 million in cash at 30 September, the rebate gives Actinogen a pro forma quarter-end cash position of A$21.9 million. The company’s September funding update had previously reported that cash balance alongside additional funding, but the new filing confirms the R&D rebate has now arrived and the borrowing used to bridge it has been cleared.
That matters because Actinogen is approaching the final data event for XanaMIA, its 247-patient Phase 2b/3 trial of Xanamem in mild to moderate Alzheimer’s disease. The double-blind, placebo-controlled study is testing a once-daily 10mg dose over 36 weeks, with the primary endpoint based on the CDR-SB dementia scale.
Mid-November Alzheimer’s Results Remain the Catalyst
Recruitment is closed and the trial has passed an independent Data Monitoring Committee review for safety and efficacy futility. Actinogen says final topline results are expected in mid-November, following the final XanaMIA patient visit completed in September. The filing provides no new efficacy data, so the cash announcement changes the funding position rather than the clinical risk.
Actinogen is also running an open-label extension in which former and current XanaMIA participants can receive Xanamem for up to 25 months. The company describes the R&D incentive as an important ongoing funding source, but the announcement does not provide a detailed cash runway estimate or say whether the A$21.9 million will cover all future development requirements.
For shareholders, the immediate tension is straightforward: Actinogen has removed the short-term debt attached to its expected rebate and enters the November readout with more cash than it held at the end of September. The next question is whether the clinical result, rather than the balance sheet, determines what funding the programme needs next.
Bottom Line?
Actinogen reaches the November readout with A$21.9 million of pro forma cash and no debt, but the clinical result will determine how far that capital ultimately goes.
Questions in the middle?
- Will the XanaMIA topline data support continued development of Xanamem in Alzheimer’s disease?
- How long will the A$21.9 million pro forma cash balance fund operations after the readout?
- Could future trials or regulatory work require additional capital even after the debt repayment?